Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure - PubMed (original) (raw)
Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure
Wei-Hsian Yin et al. Am Heart J. 2004 May.
Abstract
Background: The serum concentration of C-reactive protein (CRP) is mildly elevated in patients with chronic congestive heart failure (CHF), but this level falls well within the range found in healthy subjects. Standard clinical assays for CRP lack sensitivity within the low reference range and thus cannot be used effectively for routine clinical risk prediction. Because assays for high-sensitivity CRP (hsCRP) are now available, we can measure hsCRP to determine its predictive value for the prognosis of patients with CHF.
Methods: Serum levels of hsCRP in 108 patients with CHF and left ventricular ejection fraction (LVEF) <50% were examined. Major adverse cardiac events (death, heart transplantation, or hospitalization with worsening heart failure) during a median follow-up period of 403 days were determined.
Results: The concentrations of hsCRP in this study population were significantly increased with the severity of CHF. In a multivariate analysis, LVEF and serum levels of hsCRP were independent significant predictors for adverse outcomes in these patients (hazard ratio, 3.714, P =.024, and hazard ratio, 2.584, P =.047, respectively). However, hsCRP was minimally correlated with LVEF (r = -0.167, P =.084). Further analysis indicated that hsCRP might identify a different high-risk group and could improve risk stratification beyond that of LVEF.
Conclusions: These findings suggest that an elevated level of hsCRP is an independent predictor of prognosis in CHF and can provide additional prognostic information for the risk stratification and treatment in patients with chronic CHF.
Similar articles
- Prognostic value of high-sensitivity C-reactive protein in patients with chronic heart failure.
Xue C, Feng Y, Wo J, Li Y. Xue C, et al. N Z Med J. 2006 Nov 17;119(1245):U2314. N Z Med J. 2006. PMID: 17146489 - Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure.
Windram JD, Loh PH, Rigby AS, Hanning I, Clark AL, Cleland JG. Windram JD, et al. Am Heart J. 2007 Jun;153(6):1048-55. doi: 10.1016/j.ahj.2007.03.044. Am Heart J. 2007. PMID: 17540208 - [Prognostic value of symptoms and signs of advanced heart failure and low left ventricle ejection fraction in patients after myocardial infarction with chronic heart failure].
Kuch M, Janiszewski M, Janiszewski M, Braksator W, Mamcarz A, Sadkowska K, Kuch J, Dłuzniewski M. Kuch M, et al. Pol Merkur Lekarski. 2006 Mar;20(117):285-8. Pol Merkur Lekarski. 2006. PMID: 16780256 Clinical Trial. Polish. - High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
Sellmayer A, Limmert T, Hoffmann U. Sellmayer A, et al. Int Angiol. 2003 Mar;22(1):15-23. Int Angiol. 2003. PMID: 12771851 Review. - Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review.
Araújo JP, Lourenço P, Azevedo A, Friões F, Rocha-Gonçalves F, Ferreira A, Bettencourt P. Araújo JP, et al. J Card Fail. 2009 Apr;15(3):256-66. doi: 10.1016/j.cardfail.2008.10.030. Epub 2008 Dec 27. J Card Fail. 2009. PMID: 19327628 Review.
Cited by
- Therapeutic Use and Molecular Aspects of Ivabradine in Cardiac Remodeling: A Review.
Kamisah Y, Che Hassan HH. Kamisah Y, et al. Int J Mol Sci. 2023 Feb 1;24(3):2801. doi: 10.3390/ijms24032801. Int J Mol Sci. 2023. PMID: 36769115 Free PMC article. Review. - Effect of C-reactive protein on the risk of Heart failure: a mendelian randomization study.
Habibi D, Daneshpour MS, Asgarian S, Kohansal K, Hadaegh F, Mansourian M, Akbarzadeh M. Habibi D, et al. BMC Cardiovasc Disord. 2023 Mar 7;23(1):112. doi: 10.1186/s12872-023-03149-3. BMC Cardiovasc Disord. 2023. PMID: 36882679 Free PMC article. - Effect of a 6-month pedometer-based walking intervention on functional capacity in patients with chronic heart failure with reduced (HFrEF) and with preserved (HFpEF) ejection fraction: study protocol for two multicenter randomized controlled trials.
Vetrovsky T, Siranec M, Parenica J, Griva M, Stastny J, Precek J, Pelouch R, Bunc V, Linhart A, Belohlavek J. Vetrovsky T, et al. J Transl Med. 2017 Jul 3;15(1):153. doi: 10.1186/s12967-017-1257-x. J Transl Med. 2017. PMID: 28673328 Free PMC article. Clinical Trial. - The increased excretion of urinary orosomucoid 1 as a useful biomarker for bladder cancer.
Li F, Yu Z, Chen P, Lin G, Li T, Hou L, Du Y, Tan W. Li F, et al. Am J Cancer Res. 2016 Jan 15;6(2):331-40. eCollection 2016. Am J Cancer Res. 2016. PMID: 27186407 Free PMC article. - C-reactive protein and statins in heart failure with reduced and preserved ejection fraction.
Park JJ, Yoon M, Cho HW, Cho HJ, Kim KH, Yang DH, Yoo BS, Kang SM, Baek SH, Jeon ES, Kim JJ, Cho MC, Chae SC, Oh BH, Choi DJ. Park JJ, et al. Front Cardiovasc Med. 2022 Dec 23;9:1064967. doi: 10.3389/fcvm.2022.1064967. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36620625 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous